Literature DB >> 24487412

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.

F Ravandi1, C Arana Yi1, J E Cortes1, M Levis2, S Faderl1, G Garcia-Manero1, E Jabbour1, M Konopleva1, S O'Brien1, Z Estrov1, G Borthakur1, D Thomas1, S Pierce1, M Brandt1, K Pratz2, R Luthra3, M Andreeff1, H Kantarjian1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24487412      PMCID： PMC4091714          DOI： 10.1038/leu.2014.54

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Authors:  Mark Levis; Farhad Ravandi; Eunice S Wang; Maria R Baer; Alexander Perl; Steven Coutre; Harry Erba; Robert K Stuart; Michele Baccarani; Larry D Cripe; Martin S Tallman; Giovanna Meloni; Lucy A Godley; Amelia A Langston; Sergio Amadori; Ian D Lewis; Arnon Nagler; Richard Stone; Karen Yee; Anjali Advani; Dan Douer; W Wiktor-Jedrzejczak; Gunnar Juliusson; Mark R Litzow; Stephen Petersdorf; Miguel Sanz; Hagop M Kantarjian; Takashi Sato; Lothar Tremmel; Debra M Bensen-Kennedy; Donald Small; B Douglas Smith
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

2.  Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Authors:  Cheuk Him Man; Tsz Kan Fung; Christa Ho; Heron H C Han; Howard C H Chow; Alvin C H Ma; William W L Choi; Si Lok; Alice M S Cheung; Connie Eaves; Yok Lam Kwong; Anskar Y H Leung
Journal:  Blood       Date:  2012-02-24       Impact factor: 22.113

3.  Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Authors:  Thomas Fischer; Richard M Stone; Daniel J Deangelo; Ilene Galinsky; Elihu Estey; Carlo Lanza; Edward Fox; Gerhard Ehninger; Eric J Feldman; Gary J Schiller; Virginia M Klimek; Stephen D Nimer; D Gary Gilliland; Catherine Dutreix; Alice Huntsman-Labed; Jodi Virkus; Francis J Giles
Journal:  J Clin Oncol       Date:  2010-08-23       Impact factor: 44.544

4.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.

Authors:  Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

6.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Authors:  Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo L Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

7.  Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Authors:  Weiguo Zhang; Marina Konopleva; Yue-xi Shi; Teresa McQueen; David Harris; Xiaoyang Ling; Zeev Estrov; Alfonso Quintás-Cardama; Donald Small; Jorge Cortes; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

8.  Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

Authors:  Hubert Serve; Utz Krug; Ruth Wagner; M Cristina Sauerland; Achim Heinecke; Uta Brunnberg; Markus Schaich; Oliver Ottmann; Justus Duyster; Hannes Wandt; Thomas Fischer; Aristoteles Giagounidis; Andreas Neubauer; Albrecht Reichle; Walter Aulitzky; Richard Noppeney; Igor Blau; Volker Kunzmann; Reingard Stuhlmann; Alwin Krämer; Karl-Anton Kreuzer; Christian Brandts; Björn Steffen; Christian Thiede; Carsten Müller-Tidow; Gerhard Ehninger; Wolfgang E Berdel
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

9.  Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

Authors:  Kevin W H Yee; Marcus Schittenhelm; Anne-Marie O'Farrell; Ajia R Town; Laura McGreevey; Troy Bainbridge; Julie M Cherrington; Michael C Heinrich
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  35 in total

1.  Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Authors:  Betül Oran; Jorge Cortes; Amer Beitinjaneh; Hsiang-Chun Chen; Marcos de Lima; Keyur Patel; Farhad Ravandi; Xuemei Wang; Mark Brandt; Borje S Andersson; Stefan Ciurea; Fabio P Santos; Leandro de Padua Silva; Elizabeth J Shpall; Richard E Champlin; Hagop Kantarjian; Gautam Borthakur
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-04       Impact factor: 5.742

Review 2.  Progress in acute myeloid leukemia.

Authors:  Tapan M Kadia; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09-19

Review 3.  Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

Authors:  Christine M McMahon; Alexander E Perl
Journal:  Leuk Lymphoma       Date:  2018-09-20

4.  NFATc1 as a therapeutic target in FLT3-ITD-positive AML.

Authors:  S K Metzelder; C Michel; M von Bonin; M Rehberger; E Hessmann; S Inselmann; M Solovey; Y Wang; K Sohlbach; C Brendel; T Stiewe; J Charles; A Ten Haaf; V Ellenrieder; A Neubauer; S Gattenlöhner; M Bornhäuser; A Burchert
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

5.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment.

Authors:  Eric J Chow; Kasey J Leger; Neel S Bhatt; Daniel A Mulrooney; Colin J Ross; Sanjeev Aggarwal; Neha Bansal; Matthew J Ehrhardt; Saro H Armenian; Jessica M Scott; Borah Hong
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

6.  The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia.

Authors:  Yanhua Yue; Song Jin; Ting Xu; Jin Zhou; Liang Ma; Hongjie Shen; Depei Wu; Suning Chen; Miao Miao
Journal:  Indian J Hematol Blood Transfus       Date:  2015-08-28       Impact factor: 0.900

7.  Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Authors:  Nicholas J Short; Christopher B Benton; Hsiang-Chun Chen; Peng Qiu; Lisa Gu; Sherry Pierce; Mark Brandt; Abhishek Maiti; Taejin L Min; Kiran Naqvi; Alfonso Quintas-Cardama; Marina Konopleva; Tapan Kadia; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Elias Jabbour; Hagop Kantarjian; Michael Andreeff
Journal:  Am J Hematol       Date:  2016-08-29       Impact factor: 10.047

Review 8.  Treatment of Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Prithviraj Bose; Pankit Vachhani; Jorge E Cortes
Journal:  Curr Treat Options Oncol       Date:  2017-03

9.  A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

Authors:  Geoffrey L Uy; Sumithra J Mandrekar; Kristina Laumann; Guido Marcucci; Weiqiang Zhao; Mark J Levis; Heidi D Klepin; Maria R Baer; Bayard L Powell; Peter Westervelt; Daniel J DeAngelo; Wendy Stock; Ben Sanford; William G Blum; Clara D Bloomfield; Richard M Stone; Richard A Larson
Journal:  Blood Adv       Date:  2017-01-24

Review 10.  Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia.

Authors:  Patrick K Reville; Tapan Kadia
Journal:  Curr Treat Options Oncol       Date:  2020-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.